Johnson & Johnson Consumer France SAS – Trademark Portfolio
Entity Type: 99
Johnson & Johnson Consumer France SAS holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 3 (Cosmetics & Cleaning) — 1 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 1 trademark is registered. Notable registered marks include BIAFINE. The owner is based in 75009 Paris.
1 Rue Ccamille Desmoulins, 92130 Issy Le
75009 Paris , FR
Showing of trademarks Trademarks
Trademark Classifications
Johnson & Johnson Consumer France SAS's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Johnson & Johnson Consumer France SAS have?
Johnson & Johnson Consumer France SAS has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.
What trademark classes does Johnson & Johnson Consumer France SAS file in?
Johnson & Johnson Consumer France SAS files trademarks across 2 Nice Classification classes. The most active classes are Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals). Class 3 covers bleaching preparations and other substances for laundry use; cleaning, polishing, scouring.
What are Johnson & Johnson Consumer France SAS's most well-known trademarks?
Johnson & Johnson Consumer France SAS's registered trademark portfolio includes well-known marks such as BIAFINE. These are among 1 currently registered trademark in the portfolio.
What is Johnson & Johnson Consumer France SAS's trademark registration success rate?
Johnson & Johnson Consumer France SAS has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.